Northwest Biotherapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.12.23	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma (PR Newswire)
22.11.23	Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application (PR Newswire)
13.10.23	Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application (PR Newswire)
12.09.23	Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board (PR Newswire)
29.08.23	Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application (PR Newswire)
21.03.23	Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility (PR Newswire)
12.03.23	Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB (PR Newswire)
06.01.23	Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 (PR Newswire)
17.11.22	Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma (PR Newswire)
23.08.22	Northwest Biotherapeutics Receives Final Approval Of PIP From MHRA (RTTNews)
23.08.22	Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA (PR Newswire)
06.07.22	Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility (PR Newswire)
06.06.22	Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program (PR Newswire)
10.05.22	Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well (PR Newswire)
04.05.22	Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences (PR Newswire)
17.02.22	Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility (PR Newswire)
21.12.21	Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility (PR Newswire)
29.11.21	Northwest Biotherapeutics Announces $15 Million Financing (PR Newswire)
28.10.21	Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility (PR Newswire)
01.06.18	NW Bio discute des données intermédiaires de l'essai de phase 3 lors d'une session dans la salle de l'industrie pendant l'ASCO (PR Newswire)
01.06.18	Conférence ASCO : NW Bio discutera des données provisoires de l'essai de phase 3 lors d'une session consacrée à la scène sectorielle (PR Newswire)
01.06.18	NW Bio wird die Zwischenergebnisse seiner Phase-3-Studie auf der Sitzung im Industry Theater während der ASCO besprechen (PR Newswire)
31.05.18	NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO (PR Newswire)
31.05.18	NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO (PR Newswire)
31.05.18	NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO (PR Newswire)
31.05.18	NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO (PR Newswire)
30.05.18	NWBio annonce la publication scientifique de données de survie intermédiaires tirées de l'essai de phase 3 de DCVax®-L pour la tumeur du cerveau glioblastome (PR Newswire)
29.05.18	NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer (PR Newswire)
29.05.18	NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer (PR Newswire)
01.05.18	NW Bio Releases Vote Tallies From Special Shareholder Meeting (PR Newswire)
30.04.18	NW Bio Announces Additional Funding (PR Newswire)
21.03.18	Retailers Face "Returns Tsunami" as Try-Before-You-Buy Trend Intensifies (PR Newswire)
27.02.18	Quick Base Powers Large Organizations with New Enterprise Capabilities for Easy Adoption and Wide Deployment (PR Newswire)
20.02.18	NW Bio Congratulates Cognate BioServices On Its Management Buyout (PR Newswire)
04.12.17	NW Bio Announces Completion of $12 Million Financing (PR Newswire)
17.10.17	NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm (PR Newswire)
01.09.17	DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference (PR Newswire)
05.06.17	Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today (PR Newswire)
31.03.17	Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma (PR Newswire)
17.03.17	NW BIO Announces Registered Direct Offering Of $7.5 Million (PR Newswire)
10.03.17	NW Bio Reaches Agreement With Convertible Note Holders (PR Newswire)
21.02.17	Biotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics (PR Newswire)
07.02.17	ADHD Abuzz, All Clear For GALE's NeuVax, FDA Lifts Clinical Hold On DCVax-L (RTTNews)
06.02.17	NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached (PR Newswire)
18.01.17	NW Bio Presenting At Phacilitate Immunotherapy World Conference (PR Newswire)
20.12.16	NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Northwest Biotherapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten